X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs NATCO PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA NATCO PHARMA ABBOTT INDIA/
NATCO PHARMA
 
P/E (TTM) x 40.4 13.0 310.1% View Chart
P/BV x 10.8 2.7 395.0% View Chart
Dividend Yield % 0.6 1.6 39.2%  

Financials

 ABBOTT INDIA   NATCO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
NATCO PHARMA
Mar-18
ABBOTT INDIA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1101,080 565.7%   
Low Rs3,996671 595.3%   
Sales per share (Unadj.) Rs1,552.2592.1 262.2%  
Earnings per share (Unadj.) Rs188.8188.4 100.2%  
Cash flow per share (Unadj.) Rs196.4206.3 95.2%  
Dividends per share (Unadj.) Rs55.008.25 666.7%  
Dividend yield (eoy) %1.10.9 115.5%  
Book value per share (Unadj.) Rs796.6833.6 95.6%  
Shares outstanding (eoy) m21.2536.90 57.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.31.5 220.1%   
Avg P/E ratio x26.84.6 575.8%  
P/CF ratio (eoy) x25.74.2 606.2%  
Price / Book Value ratio x6.31.1 603.9%  
Dividend payout %29.14.4 665.2%   
Avg Mkt Cap Rs m107,37632,311 332.3%   
No. of employees `0003.34.8 68.8%   
Total wages/salary Rs m3,9373,256 120.9%   
Avg. sales/employee Rs Th9,929.34,522.5 219.6%   
Avg. wages/employee Rs Th1,185.1674.0 175.8%   
Avg. net profit/employee Rs Th1,207.71,439.0 83.9%   
INCOME DATA
Net Sales Rs m32,98521,848 151.0%  
Other income Rs m1,170404 289.6%   
Total revenues Rs m34,15522,252 153.5%   
Gross profit Rs m5,2459,284 56.5%  
Depreciation Rs m162662 24.5%   
Interest Rs m38154 24.8%   
Profit before tax Rs m6,2158,872 70.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,920 114.7%   
Profit after tax Rs m4,0126,952 57.7%  
Gross profit margin %15.942.5 37.4%  
Effective tax rate %35.421.6 163.8%   
Net profit margin %12.231.8 38.2%  
BALANCE SHEET DATA
Current assets Rs m22,65521,307 106.3%   
Current liabilities Rs m6,6815,920 112.9%   
Net working cap to sales %48.470.4 68.8%  
Current ratio x3.43.6 94.2%  
Inventory Days Days6573 88.4%  
Debtors Days Days29107 27.4%  
Net fixed assets Rs m83514,986 5.6%   
Share capital Rs m213369 57.6%   
"Free" reserves Rs m16,71530,353 55.1%   
Net worth Rs m16,92830,760 55.0%   
Long term debt Rs m00-   
Total assets Rs m24,16237,151 65.0%  
Interest coverage x163.758.6 279.3%   
Debt to equity ratio x00-  
Sales to assets ratio x1.40.6 232.1%   
Return on assets %16.819.1 87.6%  
Return on equity %23.722.6 104.9%  
Return on capital %36.929.3 125.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36910,322 3.6%   
Fx outflow Rs m3,8072,978 127.8%   
Net fx Rs m-3,4387,343 -46.8%   
CASH FLOW
From Operations Rs m1,5274,636 32.9%  
From Investments Rs m-2,148-11,155 19.3%  
From Financial Activity Rs m-1,0246,509 -15.7%  
Net Cashflow Rs m-1,646-18 9,142.2%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 7.9 7.8 100.8%  
FIIs % 0.1 16.6 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 26.0 65.8%  
Shareholders   18,270 25,395 71.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS